Compare ARK Space & Defense Innovation ETF (ARKX) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Humana Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $34.73, while Humana Inc trades at $388.83 (market cap $44.77B). The key difference: Humana Inc pays a 0.95% dividend while ARK Space & Defense Innovation ETF pays none, and Humana Inc is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKX | HUM | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $409.42 |
52-Week Low | $25.46 | $163.67 |
Market Cap | — | $44.77B |
Enterprise Value | — | $52.12B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKX trades at $34.69, up 0.81% with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on space and defense innovation, with key holdings like SpaceX and Rocket Lab. Recent news highlights strong interest in space economy ETFs as alternatives to direct SpaceX investment, with ARKX noted for outperforming peers in one-year returns despite higher volatility.
The outlook for ARKX is positive due to growing space industry tailwinds, but risks include high expense ratios and volatility. Investment appeal lies in diversified exposure to disruptive tech, though valuation concerns for holdings like SpaceX and competitive ETF options warrant caution for risk-averse investors.
Humana (HUM) trades at $388.96, up 0.9% with a neutral technical signal. The stock shows strong revenue growth reaching $129.7B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent earnings beat expectations for three consecutive quarters, while analyst consensus targets $409.93. The company maintains solid cash flow generation and recently announced key leadership appointments to strengthen its Medicaid business.
Humana presents a mixed outlook with robust revenue expansion offset by margin pressures. Investment opportunity lies in Medicare Advantage growth and cost reduction initiatives, while risks include competitive pressures and regulatory changes in healthcare. Wall Street maintains cautious optimism with 39% buy ratings amid margin recovery challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
